Navigation Links
EORTC presents European solution for effective cancer drug development
Date:7/1/2014

Drug developers are facing the perfect storm. They are confronted with major patent expiries, increased payer scrutiny, changing priorities, shifting business models, increased risk averseness, increased clinical trial costs, not to mention issues concerning R&D productivity. There needs to be a better way to identify new candidate drugs. There needs to be a new drug development pathway that is compatible with research aimed at understanding the biology of a cancer and simultaneously able to support the design and conduct of subsequent confirmatory trials, but building and maintaining such a drug development pathway is beyond the ability of individual organizations or companies. It has been argued that new forms of partnership as well as an integrated model of cancer research are needed. Now, in a paper published in Nature Reviews Clinical Oncology, the EORTC describes how collaborative molecular screening platforms could help serve these needs.

Collaborative molecular screening platforms offer a high quality integrated infrastructure for efficient screening of patients with cancer for specific molecular alterations. These identified alterations will define target populations for early trials with novel targeted agents. Pharmaceutical industry partners would be in a position to propose candidate drugs for clinical trials which could be plugged into the platform. Patients fulfilling the inclusion criteria for one or more trials would be notified by their physician and given the option of participating.

Dr. Denis Lacombe, EORTC Director and lead author of this paper says, "Collaborative molecular screening platforms will offer patients efficient access to new therapeutic agents. Clinical research will be turned on its head. Instead of designing trials which must find patients for a particular drug, the question will become which drug should be given to a particular subset of patients with an identified molecular alteration."

Collaborative molecular screening platforms are a winning proposition for all cancer drug development stakeholders. As information-sharing platforms they enable us to learn from our failures. They accommodate the integration of information from continuous risk assessments and pave the way for an adaptive licensing strategy. Importantly, they enhance the expertise of the constituent partners by combining their efforts within a cost-sharing model and could very well be the realization of personalized medicine.


'/>"/>

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Related medicine news :

1. EORTC to present cancer research results at ASCO 2014
2. NCI, NCRI and EORTC outline risk-assessment approach for biomarker-driven cancer clinical trials
3. EORTC and SIOG update expert opinion on management of elderly patients with NSCLC
4. EORTC study shows value of HRQOL assessment in small cell lung cancer
5. Joint EORTC-ESTRO session to focus on current developments in soft tissue sarcoma treatment
6. EORTC Cancer in the Elderly Task Force investigates appropriate treatment for elderly patients
7. EORTC head & neck cancer trial shows assessing HRQOL is valuable to both patients and their doctors
8. Sequential GO and chemotherapy no benefit for older AML patients according to EORTC/GIMEMA trial
9. Vaccination with GM2-KLH-QS21 does not improve outcome of melanomas patients in EORTC study
10. EORTC at 2013 ECCO-ESMO-ESTRO meeting in Amsterdam
11. Moderate dose radiotherapy effective in EORTC trial for patients with desmoid-type fibromatosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... ... San Diego physician and surgeon Dr. James Veltmeyer, author of the Medical ... the 52nd Congressional District currently held by Representative Scott Peters. , “I have ... age eleven after suffering homelessness and hardship in a distant land, I don’t just ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... The ... Excellence Awards (IDSA IDEA®) 2017 Ceremony and Gala on Aug. 19, 2017 in ... one of the world’s most prestigious and rigorous design competitions. See all the winners ...
(Date:8/20/2017)... ... August 20, 2017 , ... ... Compliance Management System has assisted multiple clients in successfully passing audits such ... Organization Control Level 2 (AICPA SOC Level 2), and State Data Use Agreement ...
(Date:8/20/2017)... ... 20, 2017 , ... Are you an adult with gluten intolerance or Celiac ... be interested in participating in a research study that focuses on family interactions when ... about the relational aspects of adults who have gluten sensitivities who cohabitate with other ...
(Date:8/19/2017)... ... ... Western University of Health Sciences will host a special symposium and exhibition about ... on Wednesday, September 6, 2017. , The symposium will be from noon to 1 ... from 1 to 3 p.m. showcasing virtual reality education technology, high speed 3-D printing ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., ... , today announced that the company has provided ... University of North Carolina at Chapel Hill and to ... designed to characterize and quantify HIV reservoir and viral ... pharmacological intervention. The HIV Cure Center is a joint ...
(Date:8/11/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global ... solutions, today announced that it will release its second ... a conference call at 9:00am ET. The Company will ... and its strategy and outlook for the remainder of ... Raphael , Chief Executive Officer, and Zvi Ben-David ...
(Date:8/8/2017)... 2017   Second-quarter ... (GAAP) loss per share from continuing operations ... increased 16 percent to $110 million ... percent to $161 million ... continuing operations increased 8 percent to $0.93 ...
Breaking Medicine Technology: